DNLI
Price
$14.87
Change
+$0.27 (+1.85%)
Updated
Apr 23 closing price
Capitalization
2.12B
19 days until earnings call
IOVA
Price
$3.19
Change
-$0.02 (-0.62%)
Updated
Apr 23 closing price
Capitalization
1.05B
19 days until earnings call
Ad is loading...

DNLI vs IOVA

Header iconDNLI vs IOVA Comparison
Open Charts DNLI vs IOVABanner chart's image
Denali Therapeutics
Price$14.87
Change+$0.27 (+1.85%)
Volume$1.48M
Capitalization2.12B
Iovance Biotherapeutics
Price$3.19
Change-$0.02 (-0.62%)
Volume$7.11M
Capitalization1.05B
DNLI vs IOVA Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IOVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. IOVA commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Buy and IOVA is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (DNLI: $14.87 vs. IOVA: $3.19)
Brand notoriety: DNLI and IOVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 102% vs. IOVA: 67%
Market capitalization -- DNLI: $2.12B vs. IOVA: $1.05B
DNLI [@Biotechnology] is valued at $2.12B. IOVA’s [@Biotechnology] market capitalization is $1.05B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileIOVA’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • IOVA’s FA Score: 0 green, 5 red.
According to our system of comparison, DNLI is a better buy in the long-term than IOVA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while IOVA’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 4 bearish.
  • IOVA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, IOVA is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а +18.49% price change this week, while IOVA (@Biotechnology) price change was +3.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.04%. For the same industry, the average monthly price growth was -8.89%, and the average quarterly price growth was -12.57%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

IOVA is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+8.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.12B) has a higher market cap than IOVA($1.05B). DNLI YTD gains are higher at: -27.036 vs. IOVA (-56.892). IOVA has higher annual earnings (EBITDA): -351.67M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. IOVA (324M). DNLI has less debt than IOVA: DNLI (48.7M) vs IOVA (58.3M). IOVA has higher revenues than DNLI: IOVA (164M) vs DNLI (0).
DNLIIOVADNLI / IOVA
Capitalization2.12B1.05B202%
EBITDA-492.89M-351.67M140%
Gain YTD-27.036-56.89248%
P/E RatioN/AN/A-
Revenue0164M-
Total Cash832M324M257%
Total Debt48.7M58.3M84%
FUNDAMENTALS RATINGS
DNLI vs IOVA: Fundamental Ratings
DNLI
IOVA
OUTLOOK RATING
1..100
156
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
37
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
3995
PRICE GROWTH RATING
1..100
6493
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IOVA's Valuation (37) in the Biotechnology industry is somewhat better than the same rating for DNLI (94). This means that IOVA’s stock grew somewhat faster than DNLI’s over the last 12 months.

IOVA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that IOVA’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (39) in the Biotechnology industry is somewhat better than the same rating for IOVA (95). This means that DNLI’s stock grew somewhat faster than IOVA’s over the last 12 months.

DNLI's Price Growth Rating (64) in the Biotechnology industry is in the same range as IOVA (93). This means that DNLI’s stock grew similarly to IOVA’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as IOVA (100). This means that DNLI’s stock grew similarly to IOVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIIOVA
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 4 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 3 days ago
80%
Declines
ODDS (%)
Bearish Trend 9 days ago
80%
Bearish Trend 8 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IOVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ICELX41.430.18
+0.44%
NYLI Epoch International Choice Inv Cl
TIBMX27.25N/A
N/A
Thornburg Investment Income Builder R5
SGMIX10.11N/A
N/A
SEI Global Managed Volatility I (SIMT)
ARAIX59.95N/A
N/A
Ariel Fund Institutional
GFSIX15.86N/A
N/A
Gabelli Global Financial Services I

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+1.85%
BEAM - DNLI
59%
Loosely correlated
+3.87%
RCKT - DNLI
57%
Loosely correlated
+2.44%
NTLA - DNLI
56%
Loosely correlated
-2.65%
ARWR - DNLI
56%
Loosely correlated
+5.26%
RGNX - DNLI
56%
Loosely correlated
+13.43%
More